Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2017 Dec 15;7(12):651. doi: 10.1038/s41408-017-0014-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Kaplan-Meier estimates of TTT according to MYD88 mutation status among all patients. Time to treatment analysis according to MYD88 mutation status in the CLL patients (N = 284). MYD88 wild-type cases (MYD88 (-)) are represented by the red line. MYD88 mutated cases (MYD88 ( + )) are represented by the blue line. b Kaplan-Meier estimates of OS according to MYD88 mutation status among all patients. Overall survival analysis according to MYD88 mutation status in the CLL patients (N = 284). MYD88 wild-type cases (MYD88 (-)) are represented by the red line. MYD88 mutated cases (MYD88 ( + )) are represented by the blue line. c Kaplan-Meier estimates of TTT according to MYD88 mutation status and IGHV mutation status among M-CLL patients. Time to treatment analysis according to MYD88 mutation status and IGHV mutation status among all CLL patients (N = 284). Of the M-CLL cases, MYD88 wild-type cases (IGHV ( + ) MYD88 (-)) are represented by the red line, while MYD88 mutated cases (IGHV ( + ) MYD88 ( + )) are represented by the blue line. IGHV unmutated cases (IGHV(-)) are represented by the green line. d Kaplan-Meier estimates of OS according to MYD88 mutation status among M-CLL patients. Overall survival analysis according to MYD88 mutation status in the M-CLL patients (N = 165). MYD88 wild-type cases (IGHV ( + ) MYD88 (-)) are represented by the red line. MYD88 mutated cases (IGHV ( + ) MYD88 ( + )) are represented by the blue line